COPENHAGEN, Denmark, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results ...

Northern Kentucky lawmaker wants overhaul of bill meant to protect income that some Kentucky hospitals say is essential for ...

The Bill & Melinda Gates Foundation, Novo Nordisk Foundation, and Wellcome are collaborating on a $50 million effort to boost ...

Replimune's innovative cancer therapies, strong cash reserves, and FDA support position it to disrupt oncology markets. Click ...

Rocket Pharmaceuticals, Inc.'s innovative therapies show promise after FDA setbacks. With potential $1B+ markets, RCKT offers ...

The National Drug Law Enforcement Agency (NDLEA) has reported that approximately 14 million Nigerians are addicted to drug ...

UnitedHealthcare supplies Medicare Supplement plans to over four million members across the U.S., according to the company.

Sonoma County commits settlement funds from opioid manufacturers to address its drug crisis, with a focus on treatment and ...

Astellas has invested heavily in novel technologies that are not necessarily the most successful or popular in the industry.

The drug supply is constantly evolving, and some experts suggest that a “fourth wave” of the opioid epidemic is underway, in which illicit fentanyl is more frequently mixed with other drugs.

Adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas that are not amenable ...

Q1 2025 Management View CEO Christopher Missling highlighted key updates on the Alzheimer's treatment, blarcamesine. He emphasized the potential of the drug to offer "a scalable treatment alternative ...